EDIG is on the verge of taking a significant step forward that carries huge ramifications for this investment. While the targets of the patent litigation continue to grow exponentially from their early beginnings of a decade or less ago, EDIG's stock acts as if it has no stake in this growth.

The focus of this board is not on the investment but rather with those obsessions of past personal issues, as we approach day 90 post Markman. Why this occurs now, on day 89 post Markman, is beyond me.

If this was a money losing biotech company with rumors of a new drug trial about to surface, this stock would be trading about $4/share with massive volume. However, the endless squabbles of who was right and the convoluted arguments associated with such, bury this investment from the savvy speculative investor.

It's hard enough to get this story out, being a otcbb, but when those in the know would rather disrupt than focus on a single purpose, there is no credibility or draw to this investment.

Certainly good news will attract new investment dollars but the surge upward would be greater and the opportunity better if investors would unite behind the single purpose.

With the obvious risks of a speculative investment aside, EDIG is nearing a break out moment given a successful Markman.

GLTA

DB